Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes

References

• Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch. Intern. Med.145(9), 1621–1629 (1985).
   PubMed Web of Science ®Google Scholar
• Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch. Intern. Med.160(4), 501–509 (2000).
   PubMed Web of Science ®Google Scholar
• Gaynes R, Edwards JR. Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis.41(6), 848–854 (2005).
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control32(8), 470–485 (2004).
   PubMed Web of Science ®Google Scholar
• Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob. Agents Chemother.48(12), 4606–4610 (2004).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J. Med. Microbiol.55(Pt 12), 1619–1629 (2006).
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis.32(Suppl. 2), S146–S155 (2001).
   PubMed Web of Science ®Google Scholar
• Tam VH, Chang KT, Abdelraouf K et al. Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.54(3), 1160–1164 (2010).
   PubMed Web of Science ®Google Scholar
• Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis.48(12), 1724–1728 (2009).
   PubMed Web of Science ®Google Scholar
• Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int. J. Antimicrob. Agents34(5), 434–438 (2009).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit. Care10(1), R27 (2006).
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Vigliani GA, Fowler VG Jr et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin. Infect. Dis.48(6), 713–721 (2009).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother.60(6), 1206–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Yuan Z, Tam VH. Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin. Investig. Drugs17(5), 661–668 (2008).
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis.6(9), 589–601 (2006).
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis.34(5), 634–640 (2002).
   PubMed Web of Science ®Google Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis.43(Suppl. 2), S49–S56 (2006).
   PubMed Web of Science ®Google Scholar
• Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs64(2), 159–204 (2004).
   PubMed Web of Science ®Google Scholar
• Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs69(12), 1555–1623 (2009).
   PubMed Web of Science ®Google Scholar
• Li XZ, Barre N, Poole K. Influence of the MexA-MexB-oprM multidrug efflux system on expression of the MexC-MexD-oprJ and MexE-MexF-oprN multidrug efflux systems in Pseudomonas aeruginosa. J. Antimicrob. Chemother.46(6), 885–893 (2000).
   PubMed Web of Science ®Google Scholar
• Poole K. Efflux-mediated multiresistance in Gram-negative bacteria. Clin. Microbiol. Infect.10(1), 12–26 (2004).
   PubMed Web of Science ®Google Scholar
• Kotra LP, Haddad J, Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob. Agents Chemother.44(12), 3249–3256 (2000).
   PubMed Web of Science ®Google Scholar
• Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis.45(1), 88–94 (2007).
   PubMed Web of Science ®Google Scholar
• Doi Y, Wachino J, Arakawa Y. Nomenclature of plasmid-mediated 16S rRNA methylases responsible for panaminoglycoside resistance. Antimicrob. Agents Chemother.52(6), 2287–2288 (2008).
   PubMed Web of Science ®Google Scholar
• Galimand M, Sabtcheva S, Courvalin P, Lambert T. Worldwide disseminated armA aminoglycoside resistance methylase gene is borne by composite transposon Tn1548. Antimicrob. Agents Chemother.49(7), 2949–2953 (2005).
   PubMed Web of Science ®Google Scholar
• Yamane K, Wachino J, Doi Y, Kurokawa H, Arakawa Y. Global spread of multiple aminoglycoside resistance genes. Emerg. Infect. Dis.11(6), 951–953 (2005).
   PubMed Web of Science ®Google Scholar
• Tam VH, Schilling AN, LaRocco MT et al. Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin. Microbiol. Infect.13(4), 413–418 (2007).
   PubMed Web of Science ®Google Scholar
• Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother.44(3), 710–712 (2000).
   PubMed Web of Science ®Google Scholar
• Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol.9(5), 461–465 (2006).
   PubMed Web of Science ®Google Scholar
• Ramadhan AA, Hegedus E. Survivability of vancomycin resistant enterococci and fitness cost of vancomycin resistance acquisition. J. Clin. Pathol.58(7), 744–746 (2005).
   PubMed Web of Science ®Google Scholar
• Criswell D, Tobiason VL, Lodmell JS, Samuels DS. Mutations conferring aminoglycoside and spectinomycin resistance in Borrelia burgdorferi. Antimicrob. Agents Chemother.50(2), 445–452 (2006).
   PubMed Web of Science ®Google Scholar
• Deptula A, Gospodarek E. Reduced expression of virulence factors in multidrug-resistant Pseudomonas aeruginosa strains. Arch. Microbiol.192(1), 79–84 (2009).
   PubMed Web of Science ®Google Scholar
• Sanchez P, Linares JF, Ruiz-Diez B et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J. Antimicrob. Chemother.50(5), 657–664 (2002).
   PubMed Web of Science ®Google Scholar
• Ohmagari N, Hanna H, Graviss L et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer104(1), 205–212 (2005).
   PubMed Web of Science ®Google Scholar
• Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother.50(1), 43–48 (2006).
   PubMed Web of Science ®Google Scholar
• Paramythiotou E, Lucet JC, Timsit JF et al. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect. Dis.38(5), 670–677 (2004).
   PubMed Web of Science ®Google Scholar
• Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J. Hosp. Infect.57(2), 112–118 (2004).
   PubMed Web of Science ®Google Scholar
• Arruda EA, Marinho IS, Boulos M et al. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol.20(9), 620–623 (1999).
   PubMed Web of Science ®Google Scholar
• Kumar A, Ellis P, Arabi Y et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest136(5), 1237–1248 (2009).
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med.34(6), 1589–1596 (2006).
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Park WB et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob. Agents Chemother.49(2), 760–766 (2005).
   PubMed Web of Science ®Google Scholar
• Fraser A, Paul M, Almanasreh N et al. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am. J. Med.119(11), 970–976 (2006).
   PubMed Web of Science ®Google Scholar
• Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J. Intern. Med.244(5), 379–386 (1998).
   PubMed Web of Science ®Google Scholar
• Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin. Infect. Dis.47(Suppl. 1), S3–S13 (2008).
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Viscoli C. Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy? Curr. Med. Chem.15(5), 517–522 (2008).
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Kim HB et al.Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin. Infect. Dis.37(6), 745–751 (2003).
   PubMed Web of Science ®Google Scholar
• Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother.49(4), 1306–1311 (2005).
   PubMed Web of Science ®Google Scholar
• Osih RB, McGregor JC, Rich SE et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother.51(3), 839–844 (2007).
   PubMed Web of Science ®Google Scholar
• Lodise TP Jr, Patel N, Kwa A et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob. Agents Chemother.51(10), 3510–3515 (2007).
   PubMed Web of Science ®Google Scholar
• Vidal F, Mensa J, Almela M et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch. Intern. Med.156(18), 2121–2126 (1996).
   PubMed Web of Science ®Google Scholar
• Yuan Z, Ledesma KR, Singh R, Hou J, Prince RA, Tam VH. Quantitative assessment of combination antimicrobial therapy against multidrug-resistant bacteria in a murine pneumonia model. J. Infect. Dis.201(6), 889–897 (2010).
   PubMed Web of Science ®Google Scholar
• Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother.47(9), 2756–2764 (2003).
   PubMed Web of Science ®Google Scholar
• Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect. Dis.4(8), 519–527 (2004).
   PubMed Web of Science ®Google Scholar
• Paul M, Leibovici L. Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect. Dis. Clin. North Am.23(2), 277–293 (2009).
   PubMed Web of Science ®Google Scholar
• Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. β lactam antibiotic monotherapy versus β lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst. Rev. (1), CD003344 (2006).
   PubMedGoogle Scholar
• Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, Lautenbach E. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am. J. Med.119(6), 526 e519–525 (2006).
   PubMed Web of Science ®Google Scholar
• Laupland KB, Parkins MD, Church DL et al. Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-β-lactamase (MBL)-producing strains. J. Infect. Dis.192(9), 1606–1612 (2005).
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev,20(3), 440–458 (2007).
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol.27(9), 893–900 (2006).
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Synnestvedt M, Weiner MG et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol.31(1), 47–53 (2010).
   PubMed Web of Science ®Google Scholar
• Hirakata Y, Yamaguchi T, Nakano M et al. Clinical and bacteriological characteristics of IMP-type metallo-β-lactamase-producing Pseudomonas aeruginosa. Clin. Infect. Dis.37(1), 26–32 (2003).
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis.36(11), 1433–1437 (2003).
   PubMed Web of Science ®Google Scholar
• Tam VH, Chang KT, Schilling AN, LaRocco MT, Genty LO, Garey KW. Impact of AmpC overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn. Microbiol. Infect. Dis.63(3), 279–285 (2009).
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch. Intern. Med.159(10), 1127–1132 (1999).
   PubMed Web of Science ®Google Scholar
• Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am. J. Infect. Control33(9), 501–509 (2005).
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis.48(1), 1–12 (2009).
   PubMed Web of Science ®Google Scholar
• Roberts RR, Hota B, Ahmad I et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin. Infect. Dis.49(8), 1175–1184 (2009).
   PubMed Web of Science ®Google Scholar
• Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant Gram-negative bacteria. Antimicrob. Agents Chemother.54(1), 109–115 (2010).
   PubMed Web of Science ®Google Scholar
• Evans HL, Lefrak SN, Lyman J et al. Cost of Gram-negative resistance. Crit. Care Med.35(1), 89–95 (2007).
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med.162(2), 185–190 (2002).
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother.50(4), 1257–1262 (2006).
   PubMed Web of Science ®Google Scholar
• Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin. Infect. Dis.28(5), 1128–1133 (1999).
   PubMed Web of Science ®Google Scholar
• Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA289(7), 885–888 (2003).
   PubMed Web of Science ®Google Scholar